August 16, 2024 The U.S. Food and Drug Administration has approved Galderma’s Nemluvio (nemolizumab) for adult patients living with prurigo nodularis. Nemluvio, administered as a prefilled pen for subcutaneous injection, inhibits interleukin-31 cytokine signaling, which is known to drive itch and is involved in inflammation, altered epidermal differentiation, and fibrosis in prurigo nodularis. The approval...